cirm.ca.gov

Autologous CD22 CAR T Cells Following Commercial CD19 CAR T Cells in B Cell Malignancies

Get the latest CIRM news, information on upcoming meetings, and funding opportunities delivered to your inbox.
cirm.ca.gov

Study of Efficacy and Safety of Tisagenlecleucel in HR B-ALL EOC MRD Positive Patients

Get the latest CIRM news, information on upcoming meetings, and funding opportunities delivered to your inbox.
cirm.ca.gov

Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) for the Treatment of Intermediate or High Grade B-Cell Non-Hodgkin Lymphoma

Get the latest CIRM news, information on upcoming meetings, and funding opportunities delivered to your inbox.
cirm.ca.gov

Evaluate Safety of Axicabtagene Ciloleucel Reinfusion (Axi-Cel-2) in Patients With Relapsed and/or Refractory Second Line High-Risk Non-Hodgkin Lymphoma After Standard of Care ...

Get the latest CIRM news, information on upcoming meetings, and funding opportunities delivered to your inbox.
cirm.ca.gov

A Phase I/II Study to Evaluate AZD5851 in GPC3+ Advanced/Recurrent Hepatocellular Carcinoma

Get the latest CIRM news, information on upcoming meetings, and funding opportunities delivered to your inbox.
cirm.ca.gov

Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.

Get the latest CIRM news, information on upcoming meetings, and funding opportunities delivered to your inbox.
cirm.ca.gov

Transplantation of Clustered Regularly Interspaced Short Palindromic Repeats Modified Hematopoietic Progenitor Stem Cells (CRISPR_SCD001) in Patients with Severe Sickle Cell ...

Get the latest CIRM news, information on upcoming meetings, and funding opportunities delivered to your inbox.
cirm.ca.gov

Study to Check the Safety of Fazirsiran and Learn if Fazirsiran Can Help People With Liver Disease and Scarring (Fibrosis) Due to an Abnormal Version of Alpha-1 Antitrypsin Protein

Get the latest CIRM news, information on upcoming meetings, and funding opportunities delivered to your inbox.
cirm.ca.gov

Expanded Access Study for the Treatment of Patients With Commercially Out-of-Specification Axicabtagene Ciloleucel

Get the latest CIRM news, information on upcoming meetings, and funding opportunities delivered to your inbox.
cirm.ca.gov

Modified Immune Cells (CD19 CAR T Cells) and Acalabrutinib for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

Get the latest CIRM news, information on upcoming meetings, and funding opportunities delivered to your inbox.